WallStSmart

Iron Mountain Incorporated (IRM)vsJanus Living, Inc. (JAN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Iron Mountain Incorporated generates 1005% more annual revenue ($7.25B vs $655.41M). IRM leads profitability with a 3.8% profit margin vs -0.0%. IRM earns a higher WallStSmart Score of 64/100 (C+).

IRM

Buy

64

out of 100

Grade: C+

Growth: 8.7Profit: 7.0Value: 2.0Quality: 6.5
Piotroski: 2/9Altman Z: 0.10

JAN

Avoid

32

out of 100

Grade: F

Growth: 8.0Profit: 3.0Value: 5.0Quality: 5.3
Piotroski: 4/9Altman Z: 1.64
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

IRMSignificantly Overvalued (-41.5%)

Margin of Safety

-41.5%

Fair Value

$70.83

Current Price

$124.66

$53.83 premium

UndervaluedFair: $70.83Overvalued

Intrinsic value data unavailable for JAN.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IRM5 strengths · Avg: 9.2/10
Return on EquityProfitability
225.1%10/10

Every $100 of equity generates 225 in profit

EPS GrowthGrowth
860.0%10/10

Earnings expanding 860.0% YoY

Debt/EquityHealth
-16.2310/10

Conservative balance sheet, low leverage

Operating MarginProfitability
21.0%8/10

Strong operational efficiency at 21.0%

Revenue GrowthGrowth
21.6%8/10

Revenue surging 21.6% year-over-year

JAN2 strengths · Avg: 9.0/10
Revenue GrowthGrowth
34.5%10/10

Revenue surging 34.5% year-over-year

Price/BookValuation
2.2x8/10

Reasonable price relative to book value

Areas to Watch

IRM4 concerns · Avg: 2.5/10
Profit MarginProfitability
3.8%3/10

3.8% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

PEG RatioValuation
2.702/10

Expensive relative to growth rate

P/E RatioValuation
138.3x2/10

Premium valuation, high expectations priced in

JAN4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Altman Z-ScoreHealth
1.644/10

Distress zone — elevated risk

Operating MarginProfitability
0.5%3/10

Operating margin of 0.5%

Return on EquityProfitability
-0.1%2/10

ROE of -0.1% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : IRM

The strongest argument for IRM centers on Return on Equity, EPS Growth, Debt/Equity. Revenue growth of 21.6% demonstrates continued momentum.

Bull Case : JAN

The strongest argument for JAN centers on Revenue Growth, Price/Book. Revenue growth of 34.5% demonstrates continued momentum.

Bear Case : IRM

The primary concerns for IRM are Profit Margin, Piotroski F-Score, PEG Ratio. A P/E of 138.3x leaves little room for execution misses. Thin 3.8% margins leave little buffer for downturns.

Bear Case : JAN

The primary concerns for JAN are EPS Growth, Altman Z-Score, Operating Margin.

Key Dynamics to Monitor

IRM profiles as a growth stock while JAN is a hypergrowth play — different risk/reward profiles.

JAN is growing revenue faster at 34.5% — sustainability is the question.

JAN generates stronger free cash flow (13M), providing more financial flexibility.

Monitor REIT - SPECIALTY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

IRM scores higher overall (64/100 vs 32/100) and 21.6% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Iron Mountain Incorporated

REAL ESTATE · REIT - SPECIALTY · USA

Iron Mountain Inc. (NYSE: IRM) is an American enterprise information management services company founded in 1951 and headquartered in Boston, Massachusetts.

Janus Living, Inc.

REAL ESTATE · REIT - RESIDENTIAL · USA

JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for pain management. The company is headquartered in Las Vegas, Nevada.

Want to dig deeper into these stocks?